Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study.

North County Endocrine Medical Group, Escondido, California, USA.
Diabetes Technology &amp Therapeutics (Impact Factor: 2.29). 06/2007; 9(3):203-10. DOI: 10.1089/dia.2007.0205
Source: PubMed

ABSTRACT Real-time continuous glucose monitoring (CGM) was studied in 140 adults with diabetes over a 12-week period of home use. Hemoglobin A(1c)(HbA1c) was measured on day 1 (baseline) and at weeks 6 and 12.
On day 1, participants received the CGM device (STS(R) System, DexCom, Inc., San Diego, CA) and underwent training on proper use. Insertion of the first sensor was performed under staff supervision. Subjects inserted subsequent sensors on their own. After calibration, the device (a 3-day sensor, receiver, and transmitter) provided users with real-time glucose values updated at 5-min intervals, glucose trend graphs, configurable high/low alerts, and a hypoglycemia alarm (<or=55 mg/dL). Study participants were given supplies sufficient for 3 weeks of device use. Follow-up visits were performed at 3-week intervals for resupply and to download CGM data, with a final visit at the end of week 12.
Overall, a reduction in HbA1c of 0.4 +/- 0.05% (least squares mean +/- SE) was observed, P < 0.0001. Significant HbA1c reductions were observed across subgroups of subjects with both type 1 and 2 diabetes, and those delivering insulin by multiple daily injections and pumps. The largest HbA1c reduction (1.4 +/- 0.4%) was observed in subjects with baseline HbA1c >9.0%. Increased CGM use was associated with greater reductions in HbA1c.
This observational study showed that home use of real-time GCM was safe and well tolerated and associated with a clinically and statistically significant reduction in HbA1c. Large-scale randomized, controlled outcome studies of CGM are indicated.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Highlights ► 12 diabetic patients were monitored simultaneously with 2 commercial CGM. ► Analysis and comparison of postprandial error of the devices was performed. ► Delay, stationarity, probability distribution and correlations were modeled. ► High variability and non-stationarity of the error was observed. ► Simulation models were built for its use in in silico studies.
    Biomedical Signal Processing and Control 03/2014; 10:322–331. DOI:10.1016/j.bspc.2012.12.003 · 1.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim of this trial was to assess (1) the accuracy and precision of electrochemistry-based glucometers CONTOURLINK, CALLA, and LINUS and (2) the diabetes control using Ambulatory Glycaemic Profiles (AGP) as markers of therapeutic effectiveness. Glucometers and COBAS INTEGRA 400 Plus analyzer were used by one laboratory professional to estimate P-glucose (PG) in 112 out-patients. There were 112 sets of 12 PG estimations analyzed. In each set, means of 3 capillary PG estimations on 3 respective glucometers and on INTEGRA analyzer were calculated. The statistical program SPSS, v. 15, was applied. The mean INTEGRA PG values ranged from 2.7 to 25.3 mmol/L. There were strong correlations between mean PG on INTEGRA versus CONTOURLINK, versus CALLA, and versus LINUS; PG deviations from INTEGRA were mostly within the range ±15%. Wilcoxon Signed Rank Test revealed differences between CONTOURLINK-INTEGRA and LINUS-INTEGRA; CALLA-INTEGRA showed no difference. SD INTEGRA = 0.061 mmol/L, SD CONTOURLINK/SD CALLA/SD LINUS were 0.256/0.290/0.286 mmol/L. All patients were trained to perform defined 10-point PG profiles to adapt food, exercise, and insulin doses. The PG differences between all tested glucometers and reference values were in borderline of ISO 15197 but worthy of consideration. AGP are helpful markers of diabetes control.
    Disease markers 12/2013; 35(6):895-905. DOI:10.1155/2013/702427 · 2.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Purpose: Experience with the use of real-time continuous glucose monitoring systems (RT-CGMS) in teenagers with type 1 diabetes mellitus (T1DM) is limited. We aimed to assess the possibility of glycaemic control improvement and to characterize the group of adolescents, who may gain long-term benefits from the use of the RT-CGMS. Methods and methods: Forty T1DM patients, aged 14.6±2.1 years, with diabetes duration 7.4±3.6 years and initial HbA1c 9.3±1.5% were recruited. The analysis was based on one-month glucose sensors use, combined with the thorough family support. Patients were analysed in groups according to baseline HbA1c: below and above 7.5%, and 10.0%. Comparison between patients with or without improvement in HbA1c after 3-month follow-up was also performed. Patients' satisfaction based on the questionnaire was assessed. Results: HbA1c level in entire study group decreased after three months, from 9.3±1.0% to 8.8±1.6% (P<0.001). In the group with HbA1c improvement, reduction was the highest: 9.0±1.3% vs. 8.0±1.2% (P<0.001). Only the group with initial HbA1c>10% did not achieve significant improvement: 11.2±0.5% vs. 10.9±1.1 (P=0.06). In satisfaction questionnaire the lowest scores (negative opinion) were reported by group of patients with initial HbA1c above 10%, while the highest scores (positive opinion) were found in the group with improvement of HbA1c after 3 month follow-up. Conclusion: Short-term use of CGMS RT, united with satisfaction questionnaire, performed in poorly controlled teenagers with T1DM, can be useful in defining the group of young patients, who can benefit from long-term CGMS RT use in metabolic control improvement.
    Advances in Medical Sciences 08/2013; DOI:10.2478/ams-2013-0024 · 0.80 Impact Factor


Available from